Bronchogen Canada — 20 mg Lyophilized Vials
Peptide Bioregulator
Also known as Ala-Glu-Asp-Leu (AEDL)
Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu, a short synthetic peptide of the bioregulator class studied in research on bronchopulmonary tissue models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu, a short synthetic peptide of the bioregulator class studied in research on bronchopulmonary tissue models.
Experimental work examines short-peptide modulation of gene expression in cultured human cells under controlled conditions.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 20mg lot is being finalised and will be published here as soon as the lab returns it.
Bronchogen belongs to the family of short regulatory peptides investigated for tissue-directed activity, in this case in bronchial and lung research models. Studies of the AEDL sequence have examined epigenetic mechanisms, including effects on gene expression during cellular ageing.
The compound is a four-residue peptide, small enough that research has focused on direct peptide-DNA and peptide-chromatin interactions rather than classical receptor pharmacology.
Bronchogen arises from the Russian peptide-bioregulator research programme, which characterized a series of short tissue-directed peptides from the 1980s onward.
Subsequent work placed the AEDL sequence within a broader model of short peptides acting on gene expression and cell differentiation.
Research into the AEDL sequence centers on epigenetic regulation of gene expression in ageing human cell cultures and on peptide-directed cell differentiation. The compound-specific literature is limited relative to better-studied peptides.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Ashapkin 2015, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on bronchopulmonary, tissue or culture. This heading marks where Bronchogen is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Ashapkin 2015, Khavinson 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Khavinson 2020, Ashapkin 2015. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
The references section of this page cites 2 primary papers published between 2015 and 2020 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Bronchogen, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Bronchogen is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under short-peptide epigenetic regulation models, bronchopulmonary tissue-culture research and gene-expression and cell-ageing studies.
The 2 papers cited on this page, published between 2015 and 2020 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. Bronchogen rests on 2 cited papers (between 2015 and 2020). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Bronchogen is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Bronchogen in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
Bronchogen is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 4 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Bronchogen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
